Adient (NYSE:ADNT) Stock Price Target Lowered at UBS Group

Key Points

• UBS cut Adient’s price target from $23 to $22 but maintained its Buy rating; the new target implies 28.45% upside from the prior close.
• Analyst views are mixed: Adient has a consensus Hold rating and average price target of $24.60, with seven Buy, three Hold, and two Sell ratings.
• In its latest quarter, Adient reported EPS of $0.52, below the $0.64 estimate, while revenue of $3.73 billion beat expectations and rose 1.1% year over year.

Adient (NYSE:ADNT - Get Free Report) had its price objective dropped by equities research analysts at UBS Group from $23.00 to $22.00 in a research note issued on Thursday, Benzinga reports. The firm currently has a "buy" rating on the stock. UBS Group's target price suggests a potential upside of 28.45% from the stock's previous close.

A number of other research analysts have also issued reports on ADNT. Citigroup dropped their price target on shares of Adient from $33.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday, August 11th. Weiss Ratings downgraded shares of Adient from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, August 21st. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $28.00 price objective on shares of Adient in a report on Thursday, August 6th. Barclays dropped their target price on Adient from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Friday, October 9th. Finally, Morgan Stanley dropped their target price on Adient from $22.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Tuesday, August 18th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Adient presently has a consensus rating of "Hold" and a consensus target price of $24.60.

Adient Stock Performance

NYSE:ADNT opened at $17.13 on Thursday. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.09 and a quick ratio of 0.91. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of 9.19, a price-to-earnings-growth ratio of 0.24 and a beta of 1.64. The firm's fifty day moving average price is $17.82 and its 200 day moving average price is $20.47. Adient has a 1-year low of $15.80 and a 1-year high of $27.32.

Adient (NYSE:ADNT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, missing analysts' consensus estimates of $0.64 by ($0.12). Adient had a positive return on equity of 7.35% and a negative net margin of 0.11%. The firm had revenue of $3.73 billion for the quarter, compared to analysts' expectations of $3.62 billion. During the same quarter in the previous year, the company posted $0.52 EPS. The firm's quarterly revenue was up 1.1% compared to the same quarter last year. On average, sell-side analysts expect that Adient will post 3.11 EPS for the current year.

Insider Activity at Adient

In other Adient news, Director Peter Carlin sold 7,843 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.25, for a total transaction of $150,977.75. Following the sale, the director directly owned 38,835 shares in the company, valued at approximately $747,573.75. The trade was a 16.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.94% of the company's stock.

Institutional Trading of Adient

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in Adient by 5.1% during the first quarter. Dimensional Fund Advisors LP now owns 4,384,904 shares of the company's stock worth $88,614,000 after purchasing an additional 211,843 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Adient by 17.2% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,293,353 shares of the company's stock valued at $46,349,000 after purchasing an additional 336,306 shares during the last quarter. Bank of America Corp DE grew its holdings in Adient by 61.7% in the first quarter. Bank of America Corp DE now owns 792,543 shares of the company's stock valued at $16,017,000 after purchasing an additional 302,538 shares during the last quarter. Empowered Funds LLC increased its position in shares of Adient by 23.5% in the first quarter. Empowered Funds LLC now owns 554,572 shares of the company's stock valued at $11,208,000 after buying an additional 105,435 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in shares of Adient by 179.3% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 527,356 shares of the company's stock valued at $10,658,000 after buying an additional 338,517 shares in the last quarter. Institutional investors and hedge funds own 92.44% of the company's stock.

Adient Company Profile

Adient plc NYSE: ADNT is a global automotive supplier specializing in the design, development and manufacture of vehicle seating systems. The company supplies complete seating assemblies as well as components such as seat structures, mechanisms, foam, fabrics, leather and other trim materials.

Adient works with automakers and other automotive customers to provide seating solutions for passenger cars, trucks, sport utility vehicles and commercial vehicles. Its offerings are designed to support vehicle comfort, safety, styling, weight reduction and manufacturing efficiency, with products developed for both traditional and electrified vehicles.

The company was formed in 2016 through the separation of Johnson Controls' automotive seating business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.